- Home
- IRON vs JANX Comparison
IRON vs JANX Comparison
Compare IRON & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- JANX
- Stock Information
- Founded
- IRON 2017
- JANX 2017
- Country
- IRON United States
- JANX United States
- Employees
- IRON N/A
- JANX N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- IRON Health Care
- JANX Health Care
- Exchange
- IRON Nasdaq
- JANX Nasdaq
- Market Cap
- IRON 1.4B
- JANX 1.6B
- IPO Year
- IRON N/A
- JANX 2021
- Fundamental
- Price
- IRON $44.24
- JANX $25.56
- Analyst Decision
- IRON Strong Buy
- JANX Strong Buy
- Analyst Count
- IRON 10
- JANX 7
- Target Price
- IRON $83.80
- JANX $94.29
- AVG Volume (30 Days)
- IRON 397.9K
- JANX 929.3K
- Earning Date
- IRON 05-07-2025
- JANX 05-08-2025
- Dividend Yield
- IRON N/A
- JANX N/A
- EPS Growth
- IRON N/A
- JANX N/A
- EPS
- IRON N/A
- JANX N/A
- Revenue
- IRON N/A
- JANX $9,336,000.00
- Revenue This Year
- IRON N/A
- JANX N/A
- Revenue Next Year
- IRON N/A
- JANX $250.58
- P/E Ratio
- IRON N/A
- JANX N/A
- Revenue Growth
- IRON N/A
- JANX 28.12
- 52 Week Low
- IRON $28.25
- JANX $22.52
- 52 Week High
- IRON $68.73
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- IRON 45.99
- JANX 37.10
- Support Level
- IRON $40.36
- JANX $24.13
- Resistance Level
- IRON $47.21
- JANX $33.97
- Average True Range (ATR)
- IRON 2.87
- JANX 2.01
- MACD
- IRON 0.10
- JANX -0.61
- Stochastic Oscillator
- IRON 37.67
- JANX 14.53
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.